1 of 1
Story summary
- Eli Lilly launched its Employer Connect platform on March 5, 2026, to improve access to obesity medications for U.S. employees.
- The program addresses a coverage gap affecting nearly half of commercially insured individuals.
- Employers can choose from over 15 independent administrators to design tailored benefits.
- Zepbound, Lilly's obesity drug, is priced at $449 per month across all doses.
- Medicare will begin covering obesity medications later this year under new agreements.
